Oppenheimer Initiates Coverage On Benitec Biopharma with Outperform Rating, Announces Price Target of $35
Portfolio Pulse from Benzinga Newsdesk
Oppenheimer has initiated coverage on Benitec Biopharma with an Outperform rating and set a price target of $35.

October 16, 2024 | 9:12 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Oppenheimer has initiated coverage on Benitec Biopharma with an Outperform rating and a price target of $35, indicating a positive outlook.
The initiation of coverage with an Outperform rating and a specific price target of $35 by a reputable firm like Oppenheimer suggests a positive outlook for Benitec Biopharma. This is likely to boost investor confidence and could lead to a short-term increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100